219 related articles for article (PubMed ID: 19458614)
1. The clinical utility index as a practical multiattribute approach to drug development decisions.
Poland B; Hodge FL; Khan A; Clemen RT; Wagner JA; Dykstra K; Krishna R
Clin Pharmacol Ther; 2009 Jul; 86(1):105-8. PubMed ID: 19458614
[TBL] [Abstract][Full Text] [Related]
2. The seven types of drug discovery waste: toward a new lean for the drug industry.
Uitdehaag JC
Drug Discov Today; 2011 May; 16(9-10):369-71. PubMed ID: 21354473
[No Abstract] [Full Text] [Related]
3. Needed: system dynamics for the drug discovery process.
Sirois S; Cloutier LM
Drug Discov Today; 2008 Aug; 13(15-16):708-15. PubMed ID: 18675763
[TBL] [Abstract][Full Text] [Related]
4. Portfolio management in early stage drug discovery - a traveler's guide through uncharted territory.
Betz UA
Drug Discov Today; 2011 Jul; 16(13-14):609-18. PubMed ID: 21600301
[TBL] [Abstract][Full Text] [Related]
5. Factors influencing quality decision-making: regulatory and pharmaceutical industry perspectives.
Donelan R; Walker S; Salek S
Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):319-28. PubMed ID: 25628072
[TBL] [Abstract][Full Text] [Related]
6. Benefit-risk assessment: the use of clinical utility index.
Ouellet D
Expert Opin Drug Saf; 2010 Mar; 9(2):289-300. PubMed ID: 20175698
[TBL] [Abstract][Full Text] [Related]
7. Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development.
Wetherington JD; Pfister M; Banfield C; Stone JA; Krishna R; Allerheiligen S; Grasela DM
J Clin Pharmacol; 2010 Sep; 50(9 Suppl):31S-46S. PubMed ID: 20881215
[TBL] [Abstract][Full Text] [Related]
8. Probabilistic risk analysis: improving early drug development decision making.
Mudd PN; Groenendaal H; Bush MA; Schmith VD
Clin Pharmacol Ther; 2010 Dec; 88(6):871-5. PubMed ID: 20944562
[TBL] [Abstract][Full Text] [Related]
9. The role of translational bioinformatics in drug discovery.
Buchan NS; Rajpal DK; Webster Y; Alatorre C; Gudivada RC; Zheng C; Sanseau P; Koehler J
Drug Discov Today; 2011 May; 16(9-10):426-34. PubMed ID: 21402166
[TBL] [Abstract][Full Text] [Related]
10. Proof of concept: a PhRMA position paper with recommendations for best practice.
Cartwright ME; Cohen S; Fleishaker JC; Madani S; McLeod JF; Musser B; Williams SA
Clin Pharmacol Ther; 2010 Mar; 87(3):278-85. PubMed ID: 20130568
[TBL] [Abstract][Full Text] [Related]
11. Traditional medicine-inspired approaches to drug discovery: can Ayurveda show the way forward?
Patwardhan B; Mashelkar RA
Drug Discov Today; 2009 Aug; 14(15-16):804-11. PubMed ID: 19477288
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers in Clinical Trials--SMi Conference. 23-24 September 2009, London, UK.
Walker G
IDrugs; 2009 Nov; 12(11):673-4. PubMed ID: 19844848
[TBL] [Abstract][Full Text] [Related]
13. Does process excellence handcuff drug development?
Koenig J
Drug Discov Today; 2011 May; 16(9-10):377-81. PubMed ID: 21349347
[TBL] [Abstract][Full Text] [Related]
14. Synthetic therapeutic peptides: science and market.
Vlieghe P; Lisowski V; Martinez J; Khrestchatisky M
Drug Discov Today; 2010 Jan; 15(1-2):40-56. PubMed ID: 19879957
[TBL] [Abstract][Full Text] [Related]
15. Translational strategies for development of monoclonal antibodies from discovery to the clinic.
Tabrizi MA; Bornstein GG; Klakamp SL; Drake A; Knight R; Roskos L
Drug Discov Today; 2009 Mar; 14(5-6):298-305. PubMed ID: 19152840
[TBL] [Abstract][Full Text] [Related]
16. Organizing for innovation: towards successful translational research.
West W; Nightingale P
Trends Biotechnol; 2009 Oct; 27(10):558-61. PubMed ID: 19683820
[TBL] [Abstract][Full Text] [Related]
17. [A model for structured introduction of new drugs. The aim is to offer all patients appropriate treatment].
Gustafsson LL; Wettermark B; Kalin M; Korkmaz S; Persson ME; Almkvist H; Hjemdahl P; Julander M; Kristianson K; Ringertz B; Bergen-Dahl GT; Wilking N
Lakartidningen; 2008 Oct 15-21; 105(42):2917-22. PubMed ID: 19025148
[No Abstract] [Full Text] [Related]
18. Bilski blundering biotech.
Simmons WJ
Nat Biotechnol; 2009 Mar; 27(3):245-8. PubMed ID: 19270670
[No Abstract] [Full Text] [Related]
19. Micro- and nanofluidic systems for high-throughput biological screening.
Hong J; Edel JB; deMello AJ
Drug Discov Today; 2009 Feb; 14(3-4):134-46. PubMed ID: 18983933
[TBL] [Abstract][Full Text] [Related]
20. Decision-making in product portfolios of pharmaceutical research and development--managing streams of innovation in highly regulated markets.
Jekunen A
Drug Des Devel Ther; 2014; 8():2009-16. PubMed ID: 25364229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
